stoxline Quote Chart Rank Option Currency Glossary
  
TG Therapeutics, Inc. (TGTX)
37.91  -1.28 (-3.27%)    07-18 16:00
Open: 39.43
High: 39.54
Volume: 1,794,129
  
Pre. Close: 39.19
Low: 37.67
Market Cap: 6,018(M)
Technical analysis
2025-07-18 4:45:02 PM
Short term     
Mid term     
Targets 6-month :  46.4 1-year :  54.2
Resists First :  39.72 Second :  46.4
Pivot price 37.21
Supports First :  36.2 Second :  34.02
MAs MA(5) :  38.56 MA(20) :  37.16
MA(100) :  37.35 MA(250) :  31.13
MACD MACD :  0.4 Signal :  0.2
%K %D K(14,3) :  80.3 D(3) :  83.4
RSI RSI(14): 52.8
52-week High :  46.47 Low :  16.64
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TGTX ] has closed below upper band by 35.4%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 39.59 - 39.79 39.79 - 39.97
Low: 37.19 - 37.42 37.42 - 37.61
Close: 37.53 - 37.92 37.92 - 38.25
Company Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Headline News

Fri, 11 Jul 2025
A Note On TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE and Debt To Equity - simplywall.st

Sat, 28 Jun 2025
TG Therapeutics: Strong Execution Tempered By An Evolving Market (NASDAQ:TGTX) - Seeking Alpha

Wed, 25 Jun 2025
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha

Thu, 19 Jun 2025
Have Insiders Sold TG Therapeutics Shares Recently? - simplywall.st

Wed, 28 May 2025
TG Therapeutics: Estimates Could Soon Be Raised Again (NASDAQ:TGTX) - Seeking Alpha

Tue, 06 May 2025
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 159 (M)
Shares Float 135 (M)
Held by Insiders 9.7 (%)
Held by Institutions 63.2 (%)
Shares Short 23,700 (K)
Shares Short P.Month 22,570 (K)
Stock Financials
EPS 0.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.62
Profit Margin 10.1 %
Operating Margin 7.1 %
Return on Assets (ttm) 7.2 %
Return on Equity (ttm) 19.7 %
Qtrly Rev. Growth 90.4 %
Gross Profit (p.s.) 2.12
Sales Per Share 2.43
EBITDA (p.s.) 0.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -61 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio 151.63
PEG Ratio 0
Price to Book value 23.25
Price to Sales 15.57
Price to Cash Flow -98.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android